Finally, anti-CD9 is also tested for its anti-adhesive properties to inhibit bacterial adhesion to keratinocytes and has been shown to be effective in a tissue-engineered model of human skin infected with Staphylococcus aureus suggesting that CD9 inhibitors may be a valuable addition to current treatments of skin infection and underscore the potential of targeting CD9 in bacterial infectious diseases (99). This evidence concerns the gene CD9 and bacterial infectious disease.